MetaCap

Rapport Therapeutics Inc. (RAPP)

NASDAQ: RAPPHealth CareBiotechnology: Pharmaceutical PreparationsUSD

23.16-0.43 (-1.82%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

RAPP stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$3.17
52-week range
22.06 – 52.93
Day range
23.00 – 23.83
Volume / Avg
437.72K / 790.62K
Beta
—

52-week range

$22.06$52.93

RAPP stock today

On Nov 20, RAPP ended the session at $23.16, shedding $0.43 (1.82%), versus the S&P 500's 3.70% decline. Shares are 56.2% below their 52-week high of $52.93, set on Aug 27, 2026 and 5.0% above the 52-week low of $22.06, near the bottom of the past year's range. RAPP is down 23.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 15.0%.

Rapport Therapeutics has posted a net loss over the last twelve months (EPS of -$3.17), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Rapport Therapeutics

Company profile

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Abraham N. Ceesay M.B.A.
Headquarters
Boston, MA
Employees
84
IPO year
2024

Financial highlights

Full financials

Rapport Therapeutics reported a net loss of $111.5 million, compared with a loss of $78.3 million a year earlier. Diluted earnings per share came in at -$2.86.

Rapport Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue———
Growth———
Net income$-111.48M$-78.31M$-34.79M
EPS (diluted)$-2.86$-3.78$-23.10

Analyst forecast

Forecast

Consensus (16 analysts)

strong_buy

Avg. price target

$64.21+177.25%

  • Strong buy 1
  • Buy 15
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $47.00High $89.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.84 vs $-1.21
Surprise
+30.58%

RAPP news

All RAPP news

Rapport Therapeutics peers

Health Care sector
RAPP peer companies
CompanyPrice% ChgMarket capCompare
NRIXNurix Therapeutics Inc.12.85-5.55%$1.40Bvs RAPP
TYRATyra Biosciences Inc.20.12+1.98%$1.39Bvs RAPP
ANABAnaptysBio Inc.46.63-1.62%$1.39Bvs RAPP
ADRXADARx Pharmaceuticals Inc.12.79-9.68%$1.42Bvs RAPP
SRPTSarepta Therapeutics Inc.13.33-5.93%$1.43Bvs RAPP
KLRAKailera Therapeutics Inc.11.02-4.84%$1.43Bvs RAPP
DMRADamora Therapeutics Inc.23.22-4.44%$1.44Bvs RAPP
QUREuniQure N.V.19.35-4.35%$1.36Bvs RAPP

Indexes, lists and sector

Rapport Therapeutics stock FAQ

What is Rapport Therapeutics's stock price today?

RAPP last traded at $23.16 as of Nov 20, 4:00 PM EST, down 1.82% on the day. Prices are delayed at least 15 minutes.

Who is Rapport Therapeutics's CEO?

Mr. Abraham N. Ceesay M.B.A. is the chief executive officer of Rapport Therapeutics Inc., which has about 84 employees.

What is the RAPP 52-week high?

The 52-week high for RAPP is $52.93 and the 52-week low is $22.06. The stock is currently 56.2% below its high.

Compare RAPP